Thermo Fisher to buy Patheon for $5.2 billion to expand biopharma services
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Jefferies Remains Sidelined on Thermo Fisher Scientific (TMO) Following Announced Acquisition of PTHN
May 16, 2017 7:25 AM EDTJefferies reiterated a Hold rating and $175.00 price target on Thermo Fisher Scientific (NYSE: TMO) following the company's announced move to acquire PTHN. TMO is paying $35/sh in cash and assuming ~$2B of net debt, implying an EV of $7.2B.
The deal marks... More
